aap Implantate AG

AAQ1

Equity

ISIN DE000A3H2101 / Valor 57872565

Xetra (2024-11-21)

EUR 2.00-0.99%

aap Implantate AG
UMushroom community rating:

0.00 0 votes No rating yet

NegativeNeutralPositive

About company

aap Implantate AG, headquartered in Berlin, Germany, operates as the parent company of the aap Group, which specializes in the development, manufacturing, and distribution of medical implants. With subsidiaries including aap Implants Inc. based in Dover, Delaware, USA, MCTeQ GmbH, and MAGIC Implants GmbH, both located in Berlin, the company has established a significant presence in the medical technology sector. Additionally, aap Implantate AG holds a 4.57% stake in AEQUOS Endoprothetik GmbH. The company's portfolio primarily focuses on orthopedic implants, a field in which it aims to innovate and provide solutions that enhance patient care. Through its subsidiaries and strategic investments, aap Implantate AG leverages a combination of technological expertise and market knowledge to address the evolving needs of the healthcare industry.

Summarized from source with an LLMView SourceSector: Healthcare

Revenue Growth

aap Implantate AG reported a revenue increase of 8% in the second quarter of 2023, reaching 2.9 million EUR compared to 2.7 million EUR in the same period of the previous year. For the first half of 2023, the revenue grew by 6% to 5.9 million EUR from 5.6 million EUR in the first half of 2022. This growth underscores the company's continued positive trajectory.

Regional Performance

In the second quarter of 2023, aap Implantate AG saw significant revenue growth in the LATAM markets, with a 13% increase, and in the EMEA region, particularly in Germany, which experienced a 16% rise. The North American market also showed a 7% increase in revenue. These regional performances contributed to the overall revenue growth for the company.

Material Costs and Gross Margin

Material costs for aap Implantate AG decreased by 0.2 million EUR in the second quarter of 2023, resulting in a material cost ratio of 13%, down from 21% in the same period of the previous year. Consequently, the gross margin improved from 77% to 88% in the second quarter of 2023, indicating better cost management and efficiency.

Operating Expenses

The company's operating expenses saw a reduction, with other operating income decreasing from 0.5 million EUR in Q2 2022 to 0.2 million EUR in Q2 2023. Personnel expenses remained stable at 1.8 million EUR for the quarter. The overall cost structure improvements contributed to a better EBITDA performance.

EBITDA Improvement

aap Implantate AG reported an improved EBITDA of -0.6 million EUR for the second quarter of 2023, compared to -0.7 million EUR in the same period of the previous year. For the first half of 2023, the EBITDA improved to -1.0 million EUR from -1.2 million EUR in the first half of 2022. This improvement reflects the company's efforts in cost management and operational efficiency.

Summarized from source with an LLMView Source

Key figures

147%1Y

-48.7%3Y

-42.2%5Y

Performance

90.6%1Y

77.8%3Y

82.8%5Y

Volatility